Anteris Technologies Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

256.54

EPS

—

Div Yield, %

—

Shrs. gr., 5y

21.15%

Rev. gr., 5y

-23.02%

Revenues

-29.23%

Net income

-94m

L+23.40%

CFO

-78m

L+27.04%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.

URL

https://anteristech.com/

IPO date

Mar 24, 2004

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT